Patents by Inventor Prasad Koteswara Kapa

Prasad Koteswara Kapa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9868739
    Abstract: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salt(s) thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: January 16, 2018
    Assignee: Novartis AG
    Inventors: John Vincent Calienni, Guang-Pei Chen, Baoqing Gong, Prasad Koteswara Kapa, Vishal Saxena
  • Publication number: 20160039832
    Abstract: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salt(s) thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
    Type: Application
    Filed: October 20, 2015
    Publication date: February 11, 2016
    Applicants: Novartis AG, ASTEX Therapeutics, LTD.
    Inventors: John Vincent Calienni, Guang-Pei Chen, Baoqing Gong, Prasad Koteswara Kapa, Vishal Saxena
  • Patent number: 9193732
    Abstract: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: November 24, 2015
    Assignees: Novartis AG, Astex Therapeutics, LTD
    Inventors: John Vincent Calienni, Guang-Pei Chen, Baoqing Gong, Prasad Koteswara Kapa, Vishal Saxena
  • Publication number: 20150099760
    Abstract: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
    Type: Application
    Filed: June 18, 2014
    Publication date: April 9, 2015
    Applicant: Novartis AG
    Inventors: John Vincent Calienni, Guang-Pei Chen, Baoqing Gong, Prasad Koteswara Kapa, Vishal Saxena
  • Publication number: 20130225571
    Abstract: The invention relates to new crystalline forms of processes for manufacturing a compound of formula 5, or a stereoisomer, tautomer or a salt thereof, wherein the substituents are as defined in the specification. The invention further relates to new manufacturing processes for specific solid forms of Compound A and its salts, to such solid forms and to use of said solid forms for the therapeutic treatment of warm-blooded animals.
    Type: Application
    Filed: September 29, 2011
    Publication date: August 29, 2013
    Applicant: NOVARTIS AG
    Inventors: John Vincent Calienni, Marilyn De La Cruz, Dietmar Flubacher, Baoqing Gong, Prasad Koteswara Kapa, Piotr H. Karpinski, Hui Liu, Pascal Michel, Rasmus Mose, Maria Caterina Testa, Liladhar Murlidhar Waykole
  • Publication number: 20130217698
    Abstract: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
    Type: Application
    Filed: November 9, 2011
    Publication date: August 22, 2013
    Applicants: Astex Therapeutics LTD, Novartis AG
    Inventors: John Vincent Calienni, Guang-Pei Chen, Baoqing Gong, Prasad Koteswara Kapa, Vishal Saxena
  • Publication number: 20120115878
    Abstract: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
    Type: Application
    Filed: November 8, 2011
    Publication date: May 10, 2012
    Inventors: John Vincent Calienni, Guang-Pei Chen, Baoqing Gong, Prasad Koteswara Kapa, Vishal Saxena
  • Publication number: 20110301157
    Abstract: The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.
    Type: Application
    Filed: August 17, 2011
    Publication date: December 8, 2011
    Inventors: Guido Bold, Hans-Georg Capraro, Giorgio Caravatti, Andreas Floersheimer, Pascal Furet, Paul W. Manley, Andrea Vaupel, Carole Pissot Soldermann, Francois Gessier, Christian Schnell, Amanda Jane Littlewood-Evans, Prasad Koteswara Kapa, Joginder S. Bajwa, Xinglong Jiang
  • Publication number: 20110251171
    Abstract: Compounds of the formula provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.
    Type: Application
    Filed: June 22, 2011
    Publication date: October 13, 2011
    Inventors: Andrew Thomas Bach, Prasad Koteswara Kapa, George Tien-San Lee, Eric M. Loeser, Michael Lloyd Sabio, James Lawrence Stanton, Thalaththani Ralalage Vedananda
  • Publication number: 20100249204
    Abstract: The present invention provides calcium salts of indole derived statins of the formula wherein R1 is alkyl, cycloalkyl or aralkyl; R2, R3 and R4 are independently hydrogen, halogen or alkyl; R5 and R6 are independently hydrogen, halogen, alkyl, cycloalkyl, aralkyl, alkoxy or aralkoxy; and the hydroxyl group at the 3-position is in the R-configuration and at the 5-position in the S-configuration; or an enantiomer thereof; or a hydrate thereof; as obtainable by the methods of the present invention. More specifically, the invention provides a calcium salt of formula IA wherein R1 is isopropyl, R2 is fluorine and R3, R4, R5 and R6 are hydrogen, designated herein as Fluvastatin calcium, in a highly crystalline form. Furthermore, the present invention is directed to methods for the preparation of the crystalline Fluvastatin calcium, and to pharmaceutical compositions comprising the crystalline form.
    Type: Application
    Filed: April 28, 2010
    Publication date: September 30, 2010
    Inventors: Guang-Pei Chen, Prasad Koteswara Kapa, Paul Allen Sutton
  • Publication number: 20090299065
    Abstract: A method for preparing an alkali metal salt comprising: (a) condensing a disilyloxydiene with an aldehyde in the presence of a titanium (IV) catalyst in an inert solvent to form a 5(S)-hydroxy-3-ketoester; (b) reducing the 5(S)-hydroxy-3-ketoester to a 3(R),5(S)-dihydroxyester in the presence of a di(lower alkyl)methoxyborane; and (c) hydrolyzing the 3(R),5(S)-dihydroxyester in the presence of an aqueous base to form an alkali metal salt.
    Type: Application
    Filed: July 2, 2009
    Publication date: December 3, 2009
    Inventors: Guang-Pei Chen, Prasad Koteswara Kapa, Eric M. Loeser, Ulrich Beutler, Werner Zaugg, Michael John Girgis
  • Patent number: 7589216
    Abstract: The present invention is directed to a process for preparing intermediates that are useful to prepare certain antibacterial N-formyl hydroxylamine compounds which are peptide deformylase inhibitors. The process makes use ? ?-lactarn intermediate. Certain optically pure intermediates are also claimed.
    Type: Grant
    Filed: September 18, 2003
    Date of Patent: September 15, 2009
    Assignee: Novartis AG
    Inventors: Prasad Koteswara Kapa, Xinglong Jiang, Eric M. Loeser, Joel Slade, Mahavir Prashad, George Tien-San Lee
  • Publication number: 20090131707
    Abstract: Improved processes for preparing intermediates useful for preparing antibacterial N-[1-oxo2-alkyl-3-(N-hydroxyformamido)-propyl}-(carbonylamino-aryl or -heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes, which have one or more of the following features: (1) make use of a particular I3-lactam intermediate; (2) which make use of a particular resolving agents, enantiomerically pure substituted propionic acids, especially (R)-2-butyl-3-hydroxypropionic acid; (3) which avoid the use of hydrogen peroxide; and (4) which facilitate selective debenzylation reducing production of waste by-products.
    Type: Application
    Filed: November 17, 2008
    Publication date: May 21, 2009
    Applicant: NOVARTIS AG
    Inventors: Mahavir Prashad, Hong-Yong Kim, Bin Hu, Joel Slade, Prasad Koteswara Kapa, Michael John Girgis
  • Publication number: 20090118160
    Abstract: Compounds of the formula provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.
    Type: Application
    Filed: January 6, 2009
    Publication date: May 7, 2009
    Inventors: Andrew Thomas Bach, Prasad Koteswara Kapa, George Tien-San Lee, Eric M. Loeser, Michael Lloyd Sabio, James Lawrence Stanton, Thalaththani Ralalage Vedananda
  • Publication number: 20080287427
    Abstract: The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising en a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.
    Type: Application
    Filed: September 14, 2005
    Publication date: November 20, 2008
    Inventors: Guido Bold, Hans-Georg Capraro, Giorgio Caravatti, Andreas Floersheimer, Pascal Furet, Paul W. Manley, Andreas Vaupel, Carole Pissot Soldermann, Francois Gessier, Christian Schnell, Amanda Jane Littlewood-Evans, Prasad Koteswara Kapa, Joginder S. Bajwa, Xinglong Jiang
  • Patent number: 7452999
    Abstract: Improved processes for preparing intermediates useful for preparing antibacterial N-[1-oxo-2-alkyl-3-(N-hydroxyformamido)-propyl}-(carbonylamino-aryl or -heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes, which have one or more of the following features: (1) make use of a particular ?-lactam intermediate; (2) which make use of a particular resolving agents, enantiomerically pure substituted propionic acids, especially (R)-2-butyl-3-hydroxy-propionic acid; (3) which avoid the use of hydrogen peroxide; and (4) which facilitate selective debenzylation reducing production of waste by-products.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: November 18, 2008
    Assignee: Novartis AG
    Inventors: Mahavir Prashad, Hong-Yong Kim, Bin Hu, Joel Slade, Prasad Koteswara Kapa, Michael John Girgis
  • Publication number: 20080221336
    Abstract: This invention provides a method for preparing compounds having the structure [Formula (I)] wherein L is [Formula (A)] or [Formula (B)] in which R1 is hydrogen or optionally substituted alkyl, n is zero or 1 and m is 1; wherein R is H, halogen, optionally substituted C1-6alkyl or C1-6alkoxy; wherein Z is a bond, O or S; wherein p is an integer from 1 to 5; wherein Q is a bond provided that Z is not a bond when p is 1; or Q is O, S or —C(O)NR6— in which R6 is hydrogen, optionally substituted alkyl or cycloalkyl; or Q is —NR6—, —NR5C(O)NH— or —NR5C(O)O— in which R5 is hydrogen, alkyl or aralkyl provided that p is not 1; wherein W is cycloalkyl, aryl or heterocyclyl; or W and R6 form a 9- to 10-membered bicyclic ring, which may be optionally substituted or may contain oxygen, nitrogen or sulfur.
    Type: Application
    Filed: July 12, 2006
    Publication date: September 11, 2008
    Inventors: Christine E. Garrett, Guang-Pei Chen, George Tien-San Lee, Xinglong Jiang, Michael J. Girgis, James Anthony Vivelo, Beata Sweryda-Krawiec, Dimitris Papoutsakis, Piotr Karpinski, Prasad Koteswara Kapa, Ada Skorodinsky
  • Patent number: 7183304
    Abstract: Compounds of the formula provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: February 27, 2007
    Assignee: Novartis AG
    Inventors: Andrew Thomas Bach, Prasad Koteswara Kapa, George Tien-San Lee, Eric M. Loesser, Michael Lloyd Sabio, James Lawrence Stanton, Thalaththani Ralalage Vedananda
  • Patent number: 6835838
    Abstract: A method for preparing an alkali metal salt comprising: (a) condensing a disilyloxydiene with an aldehyde in the presence of a titanium (IV) catalyst in an inert solvent to form a 5(S)-hydroxy-3-ketoester; (b) reducing the 5(S)-hydroxy-3-ketoester to a 3(R),5(S)-dihydroxyester in the presence of a di(lower alkyl)methoxyborane; and (c) hydrolyzing the 3(R),5(S)-dihydroxyester in the presence of an aqueous base to form an alkali metal salt.
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: December 28, 2004
    Assignee: Novartis AG
    Inventors: Guang-Pei Chen, Prasad Koteswara Kapa, Eric M. Loeser, Ulrich Beutler, Werner Zaugg, Michael John Girgis
  • Publication number: 20040249154
    Abstract: A method for preparing an alkali metal salt comprising: (a) condensing a disilyloxydiene with an aldehyde in the presence of a titanium (IV) catalyst in an inert solvent to form a 5(S)-hydroxy-3-ketoester; (b) reducing the 5(S)-hydroxy-3-ketoester to a 3(R),5(S)-dihydroxyester in the presence of a di(lower alkyl)methoxyborane; and (c) hydrolyzing the 3(R),5(S)-dihydroxyester in the presence of an aqueous base to form an alkali metal salt.
    Type: Application
    Filed: July 14, 2004
    Publication date: December 9, 2004
    Inventors: Guang-Pei Chen, Prasad Koteswara Kapa, Eric M. Loeser, Ulrich Beutler, Werner Zaugg, Michael J. Girgis